{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:50:49Z","timestamp":1792086649023,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gilead Sciences,Turkey"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-026-00919-9","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:25:23Z","timestamp":1784093123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in people with HIV (PWH) in routine clinical practice in T\u00fcrkiye: 12-month outcomes from the KLIMIK HIV-TR cohort"],"prefix":"10.1186","volume":"23","author":[{"given":"Halis","family":"Akal\u0131n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuman","family":"\u0130nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"G\u00f6kengin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"\u0130nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"G\u00f6renek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fclya \u00d6zkan","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalet","family":"Altunsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehtap","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"\u015eim\u015fek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atahan","family":"\u00c7a\u011fatay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selda Sayin","family":"Kutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Asan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabri","family":"Atalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Birengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Korten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"KL\u0130M\u0130K HIV TR Working Group - Turkish Society of Clinical Microbiology and Infectious Diseases(KL\u0130M\u0130K)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcniz","family":"Kayahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Nazl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye\u015fim","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6n\u00fcl \u00c7i\u00e7ek","family":"\u015eent\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye\u015fim","family":"Ta\u015fova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sel\u00e7uk","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0131la","family":"Akhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuna","family":"Demirdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7i\u011fdem Ataman","family":"Hatipo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Kemal","family":"\u00c7elen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lkay","family":"Karao\u011flan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye\u015fim","family":"\u00c7a\u011flar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysel Kocag\u00fcl","family":"\u00c7elikba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u00e7\u0131n","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Do\u011fru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petek","family":"Konya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurg\u00fcl","family":"Ceran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Tigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket Ert\u00fcrk","family":"\u015eengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek Ya\u011fc\u0131","family":"\u00c7a\u011flay\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"\u00d6ng\u00fcr\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl\u015fen","family":"Mermut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Merve Parmaks\u0131zo\u011flu","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Sar\u0131kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bircan","family":"Kayaaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00fctfiye Nilsun","family":"Alt\u0131nal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Serra","family":"\u00d6zel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"\u00d6nal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Y\u0131ld\u0131rmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Kant\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarife","family":"Abdulleyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firuze","family":"Soyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrsel","family":"Ersan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcle","family":"\u00c7\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rem Akdemir","family":"Kalkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Seza","family":"\u0130nal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u015f\u0131l Deniz","family":"Al\u0131ravc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl Ruhsar","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Azak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Figen","family":"Kaptan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eerife Altun","family":"Demircan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnay Tuncer","family":"Ertem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Kaya","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe \u00d6zlem","family":"Mete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Akdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","unstructured":"Peters E, Iwuji C. Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: a scoping review. Antivir Ther. 2023(1). https:\/\/doi.org\/10.1177\/13596535231159030.","DOI":"10.1177\/13596535231159030"},{"key":"919_CR2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Updated Sep 25, 2025. Accessed Dec 15, 2025."},{"key":"919_CR3","unstructured":"European AIDS Clinical Society (EACS). Guidelines v13.0. Accessed Dec 15, 2025."},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir\/abacavir\/lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063\u201372.","journal-title":"Lancet"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","volume":"6","author":"DA Wahl","year":"2019","unstructured":"Wahl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir\/abacavir\/lamivudine for initial treatment of HIV-1: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e355\u201363.","journal-title":"Lancet HIV"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073\u201382.","journal-title":"Lancet"},{"key":"919_CR7","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, et al. Fixed-dose bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7:e389\u2013400.","journal-title":"Lancet HIV"},{"key":"919_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991.","journal-title":"EClinicalMedicine"},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48-week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347\u201356.","journal-title":"Lancet HIV"},{"key":"919_CR10","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, L\u00f3pez-Cort\u00e9s L, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir plus abacavir\/lamivudine in virologically suppressed adults with HIV-1: 48-week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357\u201365.","journal-title":"Lancet HIV"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1007\/s40121-023-00879-x","volume":"12","author":"L Gan","year":"2023","unstructured":"Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir plus lamivudine for switch therapy in patients with HIV-1 infection: a real-world cohort study. Infect Dis Ther. 2023;12:2581\u201393.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"919_CR12","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","volume":"73","author":"PE Sax","year":"2021","unstructured":"Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2021;73(2):e485\u201393.","journal-title":"Clin Infect Dis"},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, Brunetta J, Inciarte A, Levy I, D\u2019Arminio Monforte A, Lambert JS, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts. HIV Med. 2024;25:440\u201353.","journal-title":"HIV Med"},{"key":"919_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/jac\/dkae081","volume":"79","author":"A D\u2019Arminio Monforte","year":"2024","unstructured":"D\u2019Arminio Monforte A, Tavelli A, Di Biaggio A, Sarmati L, Marchetti GC, Bai F, et al. Long-term outcomes of bictegravir\/emtricitabine\/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort. J Antimicrob Chemother. 2024;79:1279\u201388.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"919_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/10600280231168852","volume":"58","author":"M Torralba","year":"2024","unstructured":"Torralba M, Rodr\u00edguez G, Gasca FJG, Cuadra F, Barber\u00e1 J, Geijo P, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in a multicentre cohort: real-life experience from Spain. Ann Pharmacother. 2024;58(2):140\u20137.","journal-title":"Ann Pharmacother"},{"key":"919_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jac\/dkab481","volume":"77","author":"J Ambrosioni","year":"2022","unstructured":"Ambrosioni J, Lievano JR, Berrocal L, Inciarte A, de la Mora L, Gonz\u00e1lez-Cord\u00f3n A, et al. Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022;77:1133\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"919_CR17","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/hiv.13493","volume":"24","author":"R Nasreddine","year":"2023","unstructured":"Nasreddine R, Florence E, Yombi JC, Henrard S, Darcis G, Van Praet J, et al. Efficacy, durability, and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium. HIV Med. 2023;24:914\u201324.","journal-title":"HIV Med"},{"key":"919_CR18","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/jac\/dkae138","volume":"79","author":"I Chivite","year":"2024","unstructured":"Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, et al. Effectiveness, safety and discontinuation rates of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV using real-world data: a systematic review and meta-analysis. J Antimicrob Chemother. 2024;79:1775\u201383.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"919_CR19","first-page":"A1","volume":"101","author":"L Crupi","year":"2025","unstructured":"Crupi L, Parodi A, Cenderello G, Muccio M, Blanchi S, Randazzo N, et al. Impact of baseline plasma HIV-1 RNA and viral subtype on achievement of virological suppression in people with HIV treated with bictegravir\/emtricitabine\/tenofovir alafenamide in clinical practice. Sex Transm Infect. 2025;101(Suppl 1):A1\u2013207.","journal-title":"Sex Transm Infect"},{"key":"919_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40121-025-01139-w","volume":"14","author":"J Begovac","year":"2025","unstructured":"Begovac J, Lisicar I, Pintar VR, Zidovec-Lepej S, Planinic A, Zekan S. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide introduced at the first clinical visit: a real-life single-centre retrospective cohort study. Infect Dis Ther. 2025;14:867\u201380.","journal-title":"Infect Dis Ther"},{"key":"919_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107164","volume":"63","author":"C Hidalgo-Tenorio","year":"2024","unstructured":"Hidalgo-Tenorio C, Sequera S, Vivancos MJ, Vinuesa D, Collado A, De Los SI, et al. Bictegravir\/embtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial. Int J Antimicrob Agents. 2024;63:107164.","journal-title":"Int J Antimicrob Agents"},{"key":"919_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14787210.2023.2279719","volume":"22","author":"L Gan","year":"2024","unstructured":"Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, et al. Comparison of dolutegravir+lamivudine and bictegravir\/embtricitabine\/tenofovir alafenamide in antiretroviral therapy-na\u00efve patients infected with HIV: preliminary results from clinical practice. Expert Rev Anti Infect Ther. 2024;22:877\u201384.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"919_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae630","volume":"18","author":"X Yang","year":"2024","unstructured":"Yang X, Xie X, Fu Y, Gan L, Ma S, Long H. Effectiveness and safety of bictegravir\/Embtricitabine\/Tenofovir alafenamide in late-presenting people with HIV-1 infection. Open Forum Infect Dis. 2024;18:ofae630.","journal-title":"Open Forum Infect Dis"},{"key":"919_CR24","doi-asserted-by":"crossref","unstructured":"Rampogal M, Wurapa A, Baumgarten A, Berhe M, Pozniak A, Orkin C, et al. Five-year outcomes of bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and\/or low CD4 count in two phase 3 randomized clinical trials. Presented at: IDWeek 2022; Oct 19\u201323, 2022; Washington, DC, USA.","DOI":"10.1093\/ofid\/ofac492.1082"},{"key":"919_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107016","volume":"63","author":"D Corona","year":"2024","unstructured":"Corona D, P\u00e9rez-Valero I, Camacho A, Liarte AG, Montero-Alonso M, Alem\u00e1n MR, et al. Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV late presenters. Int J Antimicrob Agents. 2024;63:107016.","journal-title":"Int J Antimicrob Agents"},{"key":"919_CR26","unstructured":"Ambrosioni J, de Lazzari E, Suanzes P, Busca C, Ruperta LR, Orviz E, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide for the treatment of primary HIV infection: the DIC-PHI clinical trial. Presented at: AIDS 2024; Jul 22\u201326, 2024; Munich, Germany."},{"key":"919_CR27","first-page":"67","volume":"26","author":"JL Blanco-Arevalo","year":"2024","unstructured":"Blanco-Arevalo JL, Garc\u00eda-Deltoro M, Torralba M, V\u00e9lez-D\u00edaz-Pallares M, Castro A, Rubio-Rodr\u00edguez D, et al. HIV-1 resistance and virologic failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review. AIDS Rev. 2024;26:67\u201379.","journal-title":"AIDS Rev"},{"key":"919_CR28","unstructured":"\u00d6zdemir A, Demir T, Polat C, Mertcan U, S\u00f6nmezer M\u00c7, Erg\u00fcnay K, \u00dcnal S, \u0130nkaya A\u00c7, P\u0131nar A. Molecular epidemiology and antiretroviral drug resistance profile, including capsid inhibitors, among treatment-na\u00efve individuals with HIV-1 in T\u00fcrkiye. HIV Med. 2025:1\u20139. Epub ahead of print."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00919-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00919-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00919-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:33:41Z","timestamp":1792085621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00919-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00919-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8852078\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"99"}}